# Immunome Inc. (IMNM) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $20.31, market value $2.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Immunome Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 4.4×**. The shares trade at 4.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -9.1%** (5-yr avg -30.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -33.5%**. Return on equity is negative because earnings are negative.
- **Return on assets: -37.2%**. Each dollar of assets produces -37.2% of profit.

## Growth
- **Revenue growth (1 yr): -23.2%**. Revenue fell 23.2% over the last year.
- **EPS growth (1 yr): 51.4%**. Earnings per share rose 51.4%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 2.4×**. It would take 2.4 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 14.69** (quick 14.69). Current assets cover the next year's liabilities 14.69 times.
- **Altman Z-score: 30.75**. A Z-score of 30.75 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Immunome Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (15 analysts). 15 analysts cover Immunome Inc.; the consensus is strong_buy, with an average price target of $35.33 (+74% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 21.9%** (YTD -8.8%, 3-mo -14.9%). The shares are up 21.9% over twelve months including dividends.
- **From 52-week high: -32.4%** (38.7% above the low). Trading 32% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): 1.66** (volatility 61%). Beta of 1.66 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IMNM · Page: https://foliofundamentals.com/stocks/imnm

Not investment advice.